Advertisement
New Zealand markets closed

  • NZX 50

    11,716.44
    +88.58 (+0.76%)
     

  • NZD/USD

    0.6126
    -0.0001 (-0.02%)
     

  • NZD/EUR

    0.5702
    -0.0002 (-0.04%)
     

  • ALL ORDS

    8,066.60
    +91.50 (+1.15%)
     

  • ASX 200

    7,828.90
    +95.20 (+1.23%)
     

  • OIL

    81.67
    +0.04 (+0.05%)
     

  • GOLD

    2,336.60
    -7.80 (-0.33%)
     

  • NASDAQ

    19,474.62
    -225.81 (-1.15%)
     

  • FTSE

    8,281.55
    +43.83 (+0.53%)
     

  • Dow Jones

    39,411.21
    +260.91 (+0.67%)
     

  • DAX

    18,325.58
    +162.06 (+0.89%)
     

  • Hang Seng

    18,113.35
    +85.64 (+0.48%)
     

  • NIKKEI 225

    39,196.82
    +392.17 (+1.01%)
     

  • NZD/JPY

    97.6010
    -0.1200 (-0.12%)
     

Karyopharm to Participate at the Jefferies Global Healthcare Conference

PR Newswire
·2-min read

NEWTON, Mass., May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

A live webcast of the event, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

ADVERTISEMENT

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html

SOURCE Karyopharm Therapeutics Inc.